Harrow: Q3 Needs To Prove The Turnaround Is Real (NASDAQ:HROW)
· seekingalpha.com
Harrow's full-year guidance demands a significant H2 performance, with Q3 and Q4 needing record-high revenues and positive EBITDA. I rate HROW stock as a Buy.
About the TPT service
Thanks for reading. At the Total Pharma Tracker, we offer most of the following:-
For investors requiring hands-on support, our in-hou...